- Home
- SIRI vs BIO Comparison
SIRI vs BIO Comparison
Compare SIRI & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIRI
- BIO
- Stock Information
- Founded
- SIRI 2013
- BIO 1952
- Country
- SIRI United States
- BIO United States
- Employees
- SIRI N/A
- BIO N/A
- Industry
- SIRI Broadcasting
- BIO Biotechnology: Laboratory Analytical Instruments
- Sector
- SIRI Consumer Discretionary
- BIO Industrials
- Exchange
- SIRI Nasdaq
- BIO Nasdaq
- Market Cap
- SIRI N/A
- BIO 6.0B
- IPO Year
- SIRI 1994
- BIO N/A
- Fundamental
- Price
- SIRI $23.85
- BIO $247.21
- Analyst Decision
- SIRI Hold
- BIO Strong Buy
- Analyst Count
- SIRI 14
- BIO 4
- Target Price
- SIRI $26.71
- BIO $324.25
- AVG Volume (30 Days)
- SIRI 3.0M
- BIO 374.0K
- Earning Date
- SIRI 07-31-2025
- BIO 07-31-2025
- Dividend Yield
- SIRI 4.52%
- BIO N/A
- EPS Growth
- SIRI N/A
- BIO N/A
- EPS
- SIRI N/A
- BIO N/A
- Revenue
- SIRI $8,605,000,000.00
- BIO $2,541,100,000.00
- Revenue This Year
- SIRI N/A
- BIO N/A
- Revenue Next Year
- SIRI N/A
- BIO $3.42
- P/E Ratio
- SIRI N/A
- BIO N/A
- Revenue Growth
- SIRI N/A
- BIO N/A
- 52 Week Low
- SIRI $18.69
- BIO $211.43
- 52 Week High
- SIRI $41.20
- BIO $387.99
- Technical
- Relative Strength Index (RSI)
- SIRI 57.76
- BIO 53.59
- Support Level
- SIRI $23.92
- BIO $245.87
- Resistance Level
- SIRI $24.92
- BIO $264.68
- Average True Range (ATR)
- SIRI 0.67
- BIO 7.33
- MACD
- SIRI 0.07
- BIO 0.49
- Stochastic Oscillator
- SIRI 62.32
- BIO 41.12
About BIO Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.